This document contains information about Prof. Fausto J. Pinto who is the Head of Cardiology at University Hospital Sta Maria-HPV and University of Lisbon in Portugal. It discloses that he has received consultancy fees and lecture fees from various pharmaceutical companies. It also contains several figures and images from various medical studies and publications related to cardiology.

1. Prof. Fausto J. Pinto, FESC, FACC
Head, Cardiology Dpt/University Hospital Sta Maria-HPV
University of Lisbon, Portugal

2. Professor Fausto J. Pinto, MD, PhD,
FESC, FASE, FACC, FSCAI
•• DisclosuresDisclosures::
President, European Society of Cardiology (ESC)President, European Society of Cardiology (ESC)
ConsultancyConsultancy, advisory boards and, advisory boards and modestmodest
lecture fees:lecture fees:
Abbott, Astra Zeneca, Bayer, Bial, BMS, Benecke,Abbott, Astra Zeneca, Bayer, Bial, BMS, Benecke,
Biotronik, Boehringher Ingelheim,Biotronik, Boehringher Ingelheim, BostonBoston
Scientific, CovidienScientific, Covidien, GE, Irokio, Medtronic,, GE, Irokio, Medtronic,
Menarini, Merck, MSD, Novartis, Pfizer, Sanofi,Menarini, Merck, MSD, Novartis, Pfizer, Sanofi,
Servier, St Jude Medical, TabukServier, St Jude Medical, Tabuk

4. Joyce E et al EJHF 2015
LV Strain Curves according to the
Primary Endpoint

5. Joyce E et al EJHF 2015

6. Event Free survival according to LV GLS
Joyce E et al EJHF 2015

9. Study design.
Negishi K et al. Eur Heart J Cardiovasc Imaging
2014;15:324-331

10. Trends of EF in three different chemo regimens, with or without beta-blocker.
Negishi K et al. Eur Heart J Cardiovasc Imaging
2014;15:324-331

11. Trends of GLS in three different chemo regimens, with or without beta-blocker.
Negishi K et al. Eur Heart J Cardiovasc Imaging
2014;15:324-331

12. Representative cases with and without beta-blocker therapy.
Negishi K et al. Eur Heart J Cardiovasc Imaging
2014;15:324-331
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author
2013. For permissions please email: journals.permissions@oup.com

13. Proposed algorithm to guide cardioprotective therapy based on sequential evaluation of LV
strain.
Negishi K et al. Eur Heart J Cardiovasc Imaging
2014;15:324-331

16. Linear regression analysis between area strain and 2D LVEF and 3D LVEF and receiver-
operating characteristic curves.
Altman M et al. Eur Heart J Cardiovasc Imaging 2014;15:316-323©

17. Linear regression and Bland–Altman analyses for global strain parameters between 2D and
3D modes.
Altman M et al. Eur Heart J Cardiovasc Imaging 2014;15:316-323©

18. Measurements of the left ventricular volumes, ejection fraction and deformation parameter
area strain, using three-dimensional speckle-tracking echocardiography.
Altman M et al. Eur Heart J Cardiovasc Imaging 2014;15:316-323©

21. A systematic review of diastolic stress tests in heart failure with preserved ejection
fraction, with proposals from the EU‐FP7 MEDIA study group
European Journal of Heart Failure
Volume 16, Issue 12, pages 1345-1361, 12 NOV 2014 DOI: 10.1002/ejhf.184
http://onlinelibrary.wiley.com/doi/10.1002/ejhf.184/full#ejhf184-fig-0001

22. A systematic review of diastolic stress tests in heart failure with preserved ejection
fraction, with proposals from the EU‐FP7 MEDIA study group
European Journal of Heart Failure
Volume 16, Issue 12, pages 1345-1361, 12 NOV 2014 DOI: 10.1002/ejhf.184
http://onlinelibrary.wiley.com/doi/10.1002/ejhf.184/full#ejhf184-fig-0002

23. A systematic review of diastolic stress tests in heart failure with preserved ejection
fraction, with proposals from the EU‐FP7 MEDIA study group
European Journal of Heart Failure
Volume 16, Issue 12, pages 1345-1361, 12 NOV 2014 DOI: 10.1002/ejhf.184
http://onlinelibrary.wiley.com/doi/10.1002/ejhf.184/full#ejhf184-fig-0003

25. Subgroup of pts with reduced systolic LVEF (≤50%) undergoing renal denervation (n = 19)
and controls (n = 3) at baseline and at 6-month follow-up.
Felix Mahfoud et al. Eur Heart J 2014;35:2224-2231

26. LV mass index at baseline and 6-month follow-up in pts undergoing
renal denervation (n = 55) and controls (n = 17)
Felix Mahfoud et al. Eur Heart J 2014;35:2224-2231

27. Subgroup of pts with reduced myocardial contractility (diastolic dysfunction, renal
denervation: n = 27; control: n = 10) at baseline and 6-month follow-up evaluated by
measurements of circumferential strain.
Felix Mahfoud et al. Eur Heart J 2014;35:2224-2231

30. Use of cardiac imaging for the management of patients
with chronic systolic heart failure.
Alessia Gimelli et al. Eur Heart J 2014;35:3417-3425

31. Example of cardiac magnetic resonance late gadolinium enhancement
patterns in different aetiologies of heart failure.
Alessia Gimelli et al. Eur Heart J 2014;35:3417-3425

32. Accuracy for predicting recovery of regional dysfunction
in heart failure patients.
Alessia Gimelli et al. Eur Heart J 2014;35:3417-3425
Late gadolinium enhancement SPECT